Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a subset of claims match the provided label excerpts (e.g., several indication outcomes, class/description, and hyperkalemia risk). Multiple efficacy-indication claims use wording not supported by the provided label text (notably 'kidney disease hospitalization' and 'non-fatal stroke'), several claims are not verifiable from the provided sections (generic availability, manufacturer, FDA/EMA approvals, trial names), and safety claims are made as 'common side effects' for hypotension/diarrhea that are not supported by the supplied label excerpts.
Category Scores
Accurate Statements
Kerendia is prescribed to reduce the risk of sustained estimated glomerular filtration rate decline in adults with chronic kidney disease associated with type 2 diabetes.
Indications and Usage (Section 1)
Kerendia is prescribed to reduce the risk of cardiovascular death in adults with chronic kidney disease associated with type 2 diabetes.
Indications and Usage (Section 1)
Kerendia is prescribed to reduce the risk of non-fatal myocardial infarction in adults with chronic kidney disease associated with type 2 diabetes.
Indications and Usage (Section 1)
Kerendia is a non-steroidal selective mineralocorticoid receptor antagonist.
Description (Section 11)
Common side effects of Kerendia include hyperkalemia (high potassium levels).
Warnings and Precautions (Section 5.1) and Serious adverse reactions (Section 6) reference hyperkalemia
Kerendia works by blocking the damaging effects of excess mineralocorticoid receptor stimulation in the kidneys and heart.
Mechanism of Action (Section 12.1) (directionally consistent MR antagonism and MR overactivation in kidney/nonepithelial including heart; exact wording not present)
Unsupported Statements
There is currently no generic version of Kerendia (finerenone) available on the market.
Not addressed in the provided label excerpts.
The only approved and available form of Kerendia is the brand-name product.
Not addressed in the provided label excerpts.
Kerendia is prescribed to reduce the risk of kidney disease hospitalization in adults with chronic kidney disease associated with type 2 diabetes.
Provided Indications and Usage (Section 1) lists heart failure hospitalization (and other outcomes) for the CKD+T2DM indication; it does not use the term 'kidney disease hospitalization' for that indication.
Kerendia is prescribed to reduce the risk of non-fatal stroke in adults with chronic kidney disease associated with type 2 diabetes.
The provided Indications and Usage (Section 1) excerpt does not list 'non-fatal stroke' as an indicated risk reduction for CKD+T2DM.
Excess mineralocorticoid receptor stimulation can be exacerbated by conditions like type 2 diabetes.
Not stated in the provided label excerpts.
Kerendia is manufactured by Bayer.
Manufacturer information is not present in the provided label excerpts.
Common side effects of Kerendia include hypotension (low blood pressure).
Hypotension is not supported as a 'common side effect' by the provided excerpts.
Common side effects of Kerendia include diarrhea.
Diarrhea is not supported as a 'common side effect' by the provided excerpts.
Kerendia has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for its indicated uses.
Provided label excerpts do not mention FDA approvals.
Kerendia has received approval from regulatory bodies such as the European Medicines Agency (EMA) for its indicated uses.
Provided label excerpts do not mention EMA approvals.
The efficacy and safety of Kerendia have been demonstrated in clinical trials, including FIDELIO-DKD.
Provided label excerpts do not include trial names or statements about FIDELIO-DKD.
The efficacy and safety of Kerendia have been demonstrated in clinical trials, including FIGARO-DKD.
Provided label excerpts do not include trial names or statements about FIGARO-DKD.
The FIDELIO-DKD and FIGARO-DKD studies formed the basis for Kerendia's regulatory approvals.
No clinical trial basis for approvals is present in the provided label excerpts.
Contradictions
Low
AI Statement
Kerendia is prescribed to reduce the risk of kidney disease hospitalization in adults with chronic kidney disease associated with type 2 diabetes.
Label Reference
Indications and Usage (Section 1) (provided excerpt specifies hospitalization for heart failure, not kidney disease hospitalization).
Low
AI Statement
Kerendia is prescribed to reduce the risk of non-fatal stroke in adults with chronic kidney disease associated with type 2 diabetes.
Label Reference
Indications and Usage (Section 1) (provided excerpt does not list non-fatal stroke for the CKD+T2DM indication).
Important Omissions
Boxed warnings
Importance:
Moderate
Contraindications
Importance:
Moderate
Dosage and administration details (including potassium/renal function monitoring and dose adjustments) to support dosing-related safety accuracy
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several efficacy claims use outcomes not supported by the provided label excerpt (kidney disease hospitalization; non-fatal stroke). Additionally, the response asserts hypotension and diarrhea as common side effects, which are not supported by the provided excerpts. Missing key label safety elements (e.g., boxed warnings/contraindications) prevents a full safety alignment assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Material indication wording is not supported by the provided label text, and multiple additional claims are either unsupported or not verifiable from the supplied label excerpts.
Suggested Improvement
Limit efficacy claims to the exact outcomes listed in the provided Indications and Usage (Section 1) excerpt (including hospitalization for heart failure, not 'kidney disease hospitalization,' and not claiming 'non-fatal stroke'). Do not state specific 'common side effects' (e.g., hypotension, diarrhea) unless supported by the label excerpts for adverse reactions. Remove or qualify claims about generic availability, manufacturer, FDA/EMA approval, and specific trial names unless those details are present in the provided prescribing information.